Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul 19;327(7407):147-9.
doi: 10.1136/bmj.327.7407.147.

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases

Eike Wrenger  1 , Regina Müller, Michael Moesenthin, Tobias Welte, Jürgen C Frölich, Klaus H Neumann
Affiliations

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases

Eike Wrenger et al. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Two electrocardiograms (ECGs) of a 63 year old patient (patient 39 in table 1). The top ECG (A) was recorded when the patient presented with muscle paralysis, bradyarrhythmia (25-35 beats/min), hypotension (blood pressure 60/30 mm Hg), and a serum potassium concentration of 9.65 mmol/l. The patient improved rapidly after immediate treatment with haemodialysis in the intensive care unit. The bottom ECG (B) was recorded six hours later, when the patient's serum potassium concentration was 4.65 mmol/l.
Figure 1
Figure 1
Two electrocardiograms (ECGs) of a 63 year old patient (patient 39 in table 1). The top ECG (A) was recorded when the patient presented with muscle paralysis, bradyarrhythmia (25-35 beats/min), hypotension (blood pressure 60/30 mm Hg), and a serum potassium concentration of 9.65 mmol/l. The patient improved rapidly after immediate treatment with haemodialysis in the intensive care unit. The bottom ECG (B) was recorded six hours later, when the patient's serum potassium concentration was 4.65 mmol/l.
See this image and copyright information in PMC

Comment in

References

    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341: 709-17. - PubMed
    1. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 1996;78: 902-7. - PubMed
    1. Millane T, Jackson G, Gibbs CR, Lip GY. ABC of heart failure: acute and chronic management strategies. BMJ 2000;320: 559-62. - PMC - PubMed
    1. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, eds. Goodman Gilman's the pharmacological basis of therapeutics. 9th ed. New York: MacGraw-Hill, 1996: 733-58.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41. - PubMed